Opening Press Conference
With ESMO President Josep Tabernero, ESMO Press Officer Pilar Garrido, ESMO 2019 Scientific Co-Chairs Jean-Yves Blay and Anton Berns will set the scene to show how this congress is going to “translate science into better cancer patient care”.
Press releases:
1629O_PR | The price of added value for new anti-cancer drugs in France 2004-17 |
1631PD_PR | Clinical Benefit and Prices of Cancer Drugs in the US and Europe |
LBA48_PR | Adjuvant or salvage radiotherapy for the treatment of localised prostate cancer? A prospectively planned aggregate data meta-analysis |
LBA49_PR | Timing of Radiotherapy (RT) After Radical Prostatectomy (RP): First Results from the RADICALS RT Randomised Controlled Trial (RCT) [NCT00541047] |
LBA38_PR | CheckMate 459: A Randomized, Multi-Center Phase 3 Study of Nivolumab (NIVO) Versus Sorafenib (SOR) as First-Line Treatment in Patients (pts) With Advanced Hepatocellular Carcinoma (aHCC) |
The price of added value for new anti-cancer drugs in France 2004-17
- Date: 27 Sep 2019
- Topic: Bioethics, legal and economic issues
BARCELONA, Spain - Many new anti-cancer medicines add little value for patients compared to standard treatment and are rarely worth the extra cost, according to results of two studies investigating links between clinical benefit and pricing in Europe and the USA, reported at the ESMO Congress 2019. (1,2)
Clinical Benefit and Prices of Cancer Drugs in the US and Europe
- Date: 27 Sep 2019
- Topic: Bioethics, legal and economic issues
BARCELONA, Spain - Many new anti-cancer medicines add little value for patients compared to standard treatment and are rarely worth the extra cost, according to results of two studies investigating links between clinical benefit and pricing in Europe and the USA, reported at the ESMO Congress 2019. (1,2)
Results of the ARTISTIC meta-analysis
The ARTISTIC collaboration meta-analysis included three randomised trials comparing adjuvant radiotherapy with early salvage radiotherapy following prostatectomy for men with localised prostate cancer: RADICALS (ISRCTN40814031), GETUG-AFU 17 (NCT00667069), and RAVES (NCT00860652). The analysis was planned before the results of the trials were known.
READ MORE (this report is linkd with the RADICALS-RT study; scroll down to see the abstract from th ARTISTIC study)
Men with Prostate Cancer can be Spared Radiotherapy after Surgery
- Date: 27 Sep 2019
- Topic: Genitourinary cancers
BARCELONA, Spain – Men with prostate cancer can be spared radiotherapy after surgery, according to late breaking results of the RADICALS-RT trial presented at the ESMO Congress 2019 in Barcelona, Spain. (1) The study answers a longstanding question about whether the benefits of radiotherapy after surgery outweigh the side-effects.
Clinical Benefit with First-Line Immunotherapy in Advanced Hepatocellular Carcinoma
- Date: 27 Sep 2019
- Topic: Gastrointestinal cancers
BARCELONA, Spain - New data have shown a trend towards clinically meaningful improvements in survival and response rates and a favorable safety profile with first-line immunotherapy compared to current standard treatment for advanced hepatocellular carcinoma (HCC). (1)